Project description:Mixed MCBA PBFM dosing of wild-type C57BL/6Crl mice. 80 mg/kg total bile acid dose (10 mg/kg individual MCBA). MCBAs included in the dosing included AlaCA, AspCA, GluCA, LeuCA, PheCA, SerCA, ThrCA, and TyrCA.
Project description:Mixed MCBA PBFM dosing of wild-type C57BL/6Crl mice. 80 mg/kg total bile acid dose (10 mg/kg individual MCBA). MCBAs included in the dosing included AlaCA, AspCA, GluCA, LeuCA, PheCA, SerCA, ThrCA, and TyrCA.
Project description:A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip
Project description:Tamoxifen, a selective estrogen receptor modulator (SERM), is an effective treatment for breast cancers. In the CD-1 mouse model, neonatal oral dosing with tamoxifen leads to the development of adenomyosis. Both 4-hydroxyestradiol and tamoxifen can form DNA-reactive metabolites and may be involved in carcinogenesis of the uterus. After comparing the uterotrophic response of several SERMs the maximal uterotrophic doses of estradiol (100mg/kg) 4-hydroxyestradiol (385mg/kg) and tamoxifen (250mg/kg) were determined. Maximal uterotrophic doses were given orally to newborn CD-1 mice on days 1 â 4 after birth and gene and pathological changes examined in the uterus at 3 months after dosing. ERKOa knockout mice were dosed orally with tamoxifen (1mg/Kg) on days 1 â 4 after birth and uterine gene expression compared with CD-1 mice. Dosing groups: Estradiol (E2): 100mg/Kg 4-hydroxyestradiol (4OHE2): 385mg/Kg Tamoxifen : 250mg/Kg ERKO mice dosed with tamoxifen (1mg/Kg) 4 dosed animals and 4 controls for each treatment group. Uteri removed at 3 months after dosing and total RNA extracted. Controls were pooled. RNA labelling, hybridisation and analysis of fluorescence was carried out as described by Turton et al (2001). Cy3/Cy5 dye swap labelling was carried out on samples from each animal. Reference: Turton NJ et. al. (Oncogene (2001) 20, 1300-1306
Project description:C57BL/6Crl mice were fed 10 mg/kg BA or control for 13 days. Samples collected on day 14. Treatment groups included serocholate, serine + cholate, phenylalanocholate, phenylalanine + cholate, taurocholate, taurine + cholate, and a mock control.
Fecal, F; Colon, CL; Cecum, CE; Duodenum, DD; Gallbladder, GB; Ileum, IL; Liver, L
Project description:The objective of this study was to determine the therapeutic effect and PK/PD relationship of Hibercell compound HC-7366 after 3 days continuous BID dosing (7 administrations) in the MOLM-16 subcutaneous leukemia xenograft model. Single point plasma concentrations were determined 1 h post dose on day 4. HC-7366 at dose levels of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg BID dosing all exhibited significant antitumor activities with TGI% values of 74.8%, 91.5%, 93.6%, 82.0%, and 62.0% (P values < 0.05 vs. vehicle control group), respectively. The maximum antitumor effects were achieved at 3 mg/kg which resulted in Partial Response (PR, ≥50% tumor regression) in 100% of animals. The plasma concentrations of HC-7366 at 1 h post dose on day 4 provided a single point determination of systemic exposure. The concentrations increased in approximate proportion to dose level across the range 0.3 – 30 mg/kg. These data indicate that HC-7366 treatment exhibits a ‘U-shaped’ dose/exposure-response relationship in this model when dosed at 0.3, 1, 3, 10 or 30 mg/kg, orally (PO), twice per day (BID). Regarding the safety profile, most animals treated with HC-7366 at dose level of 1 mg/kg and 3 mg/kg showed minor to moderate BW loss during the study period. IHC on these samples demonstrated maximal induction of the ATF4 targets ASNS, PSAT1 and PHGDH at 1 and 3 mg/kg doses, with 0.3, 10 and 30 have smaller increases over vehicle. RNA-Seq confirmed that the ASNS, PSAT1 and PHGDH effects were regulated at the mRNA level in the U-shaped manner. DDIT3, BBC3, and ATF4 mRNA also demonstrated a U-shaped upregulation, with maximal effect at 3 mg/kg. Notably, PPP1R15A, MCL1, PPP1R15B, EIF2AK4, CASP3, and EIF2S1 mRNA showed much more modest regulation. These data strongly suggest that HC-7366 is having its maximal efficacy in MOLM-16 when it is behaving as a GCN2 activator (i.e., at 1 and 3 mg/kg), where higher concentrations begin to inhibit this effect (at 10 and 30 mg/kg).